✦ LIBER ✦
Requiring an amyloid-β1–42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials
✍ Scribed by Michael C. Donohue; Anthony C. Gamst; Paul S. Aisen
- Book ID
- 118466807
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 187 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1552-5260
No coin nor oath required. For personal study only.